Submitted:
28 July 2025
Posted:
30 July 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| ICU | Intensive Care Unit |
| BMI | Body Mass Index |
| ESGO | European Society of Gynecological Oncology |
| SD | Standard Deviation |
| ASA | American Society of Anesthesiologists |
| NACT | NeoAdjuvant ChemoTherapy |
| OR | Odds Ratio |
| CI | Confidence Interval |
| ERAS | Enhanced Recovery After Surgery |
References
- PDQ Adult Treatment Editorial Board. PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US); Bethesda (MD): Mar 14, 2023. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version.
- Cabasag CJ, Fagan PJ, Ferlay J, et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151(9):1535-1541. [CrossRef]
- Chan J, Urban R, Cheung M, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95(10):1314. [CrossRef]
- Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-299.
- Ries LAG, Eisner MP, Kosary BK, et al. Editors. SEER cancer statistics review, 1975–2001, National Cancer Institute, Bethesda, MD. Bethesda, MD: http://www.seer.cancer.gov/csr/1975_2001/.
- Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. [Updated 2023 Jun 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567760/.
- Coleridge SL, Bryant A, Kehoe S, Morrison J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;7(7):CD005343. Published 2021 Jul 30. [CrossRef]
- Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I and duBois A: European Society of Gynaecological Oncology (ESGO) Guidelines for ovarian cancer surgery. Int J Gynecol Cancer 27(7): 1534-1542, 2017. [CrossRef] [PubMed]
- Yao T, DeJong SR, McGree ME, Weaver AL, Cliby WA, Kumar A. Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery. Gynecol Oncol. 2019;153(1):68-73. [CrossRef]
- Davidovic-Grigoraki M, Thomakos N, Haidopoulos D, Vlahos G and Rodolakis A: Do critical care units play a role in the management of gynaecological oncology patients? The contribution of gynaecologic oncologist in running critical care units. Eur J Cancer Care (Engl) 26(2), 2017. [CrossRef] [PubMed]
- Ross MS, Burriss ME, Winger DG, Edwards RP, Courtney-Brooks M, Boisen MM. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival. Gynecol Oncol. 2018;150(2):306-310. [CrossRef]
- Díaz-Montes TP, Zahurak ML, Bristow RE. Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer. Gynecol Oncol. 2007;107(3):464-468. [CrossRef]
- Thomakos N, Prodromidou A, Haidopoulos D, Machairas N, Rodolakis A. Postoperative Admission in Critical Care Units Following Gynecologic Oncology Surgery: Outcomes Based on a Systematic Review and Authors' Recommendations. In Vivo. 2020;34(5):2201-2208. [CrossRef]
- Amir M, Shabot MM, Karlan BY. Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications. Am J Obstet Gynecol. 1997;176(6):1389-1393. [CrossRef]
- Collins A, Spooner S, Horne J, et al. Peri-operative Variables Associated With Prolonged Intensive Care Stay Following Cytoreductive Surgery for Ovarian Cancer. Anticancer Res. 2021;41(6):3059-3065. [CrossRef]
- Brooks SE, Ahn J, Mullins CD, Baquet CR. Resources and use of the intensive care unit in patients who undergo surgery for ovarian carcinoma. Cancer. 2002;95(7):1457-1462. [CrossRef]
- Ruskin R, Urban RR, Sherman AE, et al. Predictors of intensive care unit utilization in gynecologic oncology surgery. Int J Gynecol Cancer. 2011;21(8):1336-1342. [CrossRef]
- Cai B, Li K, Li G. Impact of Obesity on Major Surgical Outcomes in Ovarian Cancer: A Meta-Analysis. Front Oncol. 2022;12:841306. Published 2022 Feb 9. [CrossRef]
- Smits A, Lopes A, Das N, et al. Surgical morbidity and clinical outcomes in ovarian cancer - the role of obesity. BJOG. 2016;123(2):300-308. [CrossRef]
- Wolfberg AJ, Montz FJ, Bristow RE. Role of obesity in the surgical management of advanced-stage ovarian cancer. J Reprod Med. 2004;49(6):473-476.
- Sobol JB, Wunsch H. Triage of high-risk surgical patients for intensive care. Crit Care. 2011;15(2):217. [CrossRef]
- Pedrosa E, Silva M, Lobo A, Barbosa J, Mourao J. Is the ASA Classification Universal?. Turk J Anaesthesiol Reanim. 2021;49(4):298-303. [CrossRef]
- Kumar A, Langstraat CL, DeJong SR, et al. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer. Gynecol Oncol. 2017;147(1):104-109. [CrossRef]
- Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54(6):991-1001. [CrossRef]
- Shen H, Pang Q, Gao Y, Liu H. Effects of epidural anesthesia on the prognosis of ovarian cancer-a systematic review and meta-analysis. BMC Anesthesiol. 2023;23(1):390. Published 2023 Nov 29. [CrossRef]
- Tseng JH, Cowan RA, Afonso AM, et al. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2018;151(2):287-293. [CrossRef]
- Moslemi-Kebria M, El-Nashar SA, Aletti GD, Cliby WA. Intraoperative hypothermia during cytoreductive surgery for ovarian cancer and perioperative morbidity. Obstet Gynecol. 2012;119(3):590-596. [CrossRef]
- Xiong J, Kurz A, Sessler DI, et al. Isoflurane produces marked and nonlinear decreases in the vasoconstriction and shivering thresholds. Anesthesiology. 1996;85(2):240-245. [CrossRef]
- Sessler, DI. Perioperative thermoregulation and heat balance. Lancet. 2016;387(10038):2655-2664. [CrossRef]
- Kaufner L, Niggemann P, Baum T, et al. Impact of brief prewarming on anesthesia-related core-temperature drop, hemodynamics, microperfusion and postoperative ventilation in cytoreductive surgery of ovarian cancer: a randomized trial. BMC Anesthesiol. 2019;19(1):161. Published 2019 Aug 22. [CrossRef]

| Patient characteristics | n=74 (%) | <48 hoursn=47 (63.5%) | 48 hoursn=27 (36.5%) |
|---|---|---|---|
| Stage, n (%) | |||
| I | 1 (1.4%) | 1 (2.1%) | 0 (0.0%) |
| III | 50 (67.6%) | 30 (63.8%) | 20 (74.1%) |
| IV | 22 (29.7%) | 16 (34.0%) | 6 (22.2%) |
| V | 1 (1.4%) | 0 (0.0%) | 1 (3.7%) |
| Tumor grade, n (%) | |||
| Grade 1 | 19 (25.7%) | 12 (25.5%) | 7 (25.9%) |
| Grade 2 | 28 (37.8%) | 16 (34.0%) | 12 (44.4%) |
| Grade 3 | 27 (36.5%) | 19 (40.4%) | 8 (29.6%) |
| Cause of icu admission | |||
| Hemodynamic support | 34 (45.9%) | 25 (53.2%) | 9 (33.3%) |
| Mechanical Ventilation | 39 (52.7%) | 22 (46.8%) | 17 (63.0%) |
| Renal replacement therapy | 1 (1.4%) | 0 (0.0%) | 1 (3.7%) |
| Perioperative/intraoperative variables | <48 hours n=47 (63.5%) |
n=27 (36.5%) |
Mean difference (95% CI) |
p-value |
|---|---|---|---|---|
| Quantitative | ||||
| Time of surgery (min) | 312.13 (77.09) | 363.15 (91.35) | -51.02 (-90.745, -11.29) | 0.013 |
| Blood loss (cc) | 757.96 (626.91) | 969.23 (561.26) | -211.27 (-509.22, 86.67) | 0.162 |
| Age (years) | 60.79 (10.77) | 56.82 (11.02) | 3.97 (-1.26, 9.20) | 0.134 |
| ΒΜΙ | 29.29 (6.88) | 31.77 (6.91) | -2.48 (-5.80, 0.84) | 0.140 |
| Ascites volume (cc) | 2368.42 (1498.16) | 2558.82 (1796.197) | -190.40 (-1306.58, 925.77) | 0.731 |
| Presurgery Hb (g/dL) | 11.93 (1.43) | 11.97 (1.59) | -0.04 (-0.745, 0.68) | 0.928 |
| Postsurgery Hb (lowest) (g/dL) | 8.64 (1.13) | 8.42 (1.81) | 0.22 (-0.56, 1.00) | 0.572 |
| Presurgery Albumin (g/dL) | 3.93 (0.57) | 3.84 (0.63) | 0.09 (-0.20, 0.39) | 0.517 |
| Postsurgery Albumin (g/dL) | 2.16 (0.62) | 2.06 (0.63) | 0.10 (-0.21, 0.42) | 0.522 |
| Presurgery Proteins (g/dL) | 6.81 (0.64) | 6.73 (1.08) | 0.08 (-0.34, 0.48) | 0.734 |
| Postsurgery Proteins (g/dL) | 3.77 (1.14) | 3.58 (1.16) | 0.19 (-0.39, 0.77) | 0.511 |
| Postsurgery body temperature (*celcius) | 35.87 (0.59) | 35.06 (0.94) | 0.81 (0.38, 1.23) | <0.001 |
| Number of Chemotherapies | 4.67 (1.13) | 3.73 (0.91) | 0.939 (0.15, 1.73) | 0.021 |
| Qualitative | ||||
| Pathological type | 0.086 | |||
| Non-serous | 5 (41.7%) | 7 (58.3%) | - | |
| Serous | 42 (67.7%) | 20 (32.3%) | - | |
| Grade | 0.595 | |||
| 1 | 12 (63.2%) | 7 (36.8%) | - | |
| 2 | 16 (57.1%) | 12 (42.9%) | - | |
| 3 | 19 (70.4%) | 8 (29.6%) | - | |
| Treatment option | 0.166 | |||
| Primary Debulking | 20 (55.6%) | 16 (44.4%) | - | |
| Interval/Late Debulking | 27 (71.1%) | 11 (28.9%) | - | |
| Ascites > 500cc | 0.091 | |||
| No | 27 (73.0%) | 10 (27.0%) | - | |
| Yes | 20 (54.1%) | 17 (45.9%) | - | |
| Pleural effusion | 0.142 | |||
| No | 37 (68.5%) | 17 (31.5%) | - | |
| Yes | 10 (50.0%) | 10 (50.0%) | - | |
| Lymphadenectomy | 0.338 | |||
| No | 33 (67.3%) | 16 (32.7%) | - | |
| Yes | 14 (56.0%) | 11 (44.0%) | - | |
| Bowel Resection | 0.742 | |||
| No | 26 (61.9%) | 16 (38.1%) | - | |
| Yes | 21 (65.6%) | 11 (34.4%) | - | |
| ASA Score | 0.624 | |||
| 1 | 16 (69.6%) | 7 (30.4%) | - | |
| 2 | 19 (57.6%) | 14 (42.4%) | - | |
| 3 | 12 (66.7%) | 6 (33.3%) | - | |
| Cause of icu admission | 0.131 | |||
| Hemodynamic support | 25 (73.5%) | 9 (26.5%) | - | |
| Mechanical Ventilation | 22 (56.4%) | 17 (43.6%) | - | |
| Renal replacement therapy | 0 (0.0%) | 1 (100.0%) | - | |
| Residual disease after surgery | 0.378 | |||
| R0 | 34 (60.7%) | 22 (39.3%) | - | |
| R1/R5 | 13 (72.2%) | 5 (27.8%) | - | |
| Epidural | 0.166 | |||
| No | 20 (55.6%) | 16 (44.4%) | - | |
| Yes | 27 (71.1%) | 11 (28.9%) | - | |
| Intra-op. complications | 0.212 | |||
| No | 30 (58.8%) | 21 (41.2%) | - | |
| Yes | 17 (73.9%) | 6 (26.1%) | - | |
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| Predictor Variables | OR | OR 95% CI | p-value | OR | OR 95% CI | p-value |
| Time of surgery (min) | 1.007 | (1.001-1.013) | 0.016 | 1.017 | (1.002-1.033) | 0.025 |
| Blood loss (cc) | 1.001 | (1.000-1.001) | 0.171 | 1.000 | (0.998-1.002) | 0.893 |
| Age (years) | 0.966 | (0.923-1.011) | 0.138 | 0.946 | (0.849-1.054) | 0.311 |
| ΒΜΙ | 1.054 | (0.983-1.131) | 0.140 | 1.215 | (1.021-1.446) | 0.028 |
| Ascites volume (cc) | 1.000 | (1.000-1.000) | 0.722 | |||
| Presurgery Hb (g/dL) | 1.015 | (0.736-1.401) | 0.927 | |||
| Postsurgery Hb (lowest) (g/dL) | 0.892 | (0.632-1.260) | 0.517 | |||
| Presurgery Albumin (g/dL) | 0.754 | (0.323-1.758) | 0.513 | |||
| Postsurgery Albumin (g/dL) | 0.767 | (0.344-1.708) | 0.516 | |||
| Presurgery Proteins (g/dL) | 0.899 | (0.492-1.643) | 0.730 | |||
| Postsurgery Proteins (g/dL) | 0.859 | (0.548-1.344) | 0.505 | |||
| Postsurgery body temperature (*celcius) | 0.220 | (0.082-0.589) | 0.003 | 0.082 | (0.013-0.507) | 0.007 |
| Pathological type - Serous (ref. Other types) |
0.340 | (0.096-1.205) | 0.095 | 0.459 | (0.060-3.531) | 0.454 |
| Grade | 0.597 | |||||
| 2 (ref. 1) | 1.286 | (0.389-4.249) | 0.680 | |||
| 3 (ref. 1) | 0.722 | (0.208-2.508) | 0.608 | |||
| Treatment option - Interval/Late Debulking (ref. Primary Debulking) | 0.509 | (0.195-1.331) | 0.169 | 0.293 | (0.033-2.629) | 0.273 |
| Ascites > 500cc - Yes | 2.295 | (0.868-6.065) | 0.094 | 2.481 | (0.234-26.327) | 0.451 |
| Pleural effusion - Yes | 2.176 | (0.763-6.207) | 0.146 | 2.350 | (0.146-37.863) | 0.547 |
| Lymphadenectomy - Yes | 1.621 | (0.602-4.361) | 0.339 | |||
| Bowel Resection - Yes | 0.851 | (0.326-2.221) | 0.742 | |||
| ASA Score | 0.626 | |||||
| 2 (ref. 1) | 1.684 | (0.547-5.187) | 0.364 | |||
| 3 (ref. 1) | 1.143 | (0.305-4.289) | 0.843 | |||
| Residual disease after surgery- R1/R5 (ref. R0) | 0.594 | (0.186-1.901) | 0.380 | |||
| Epidural - Yes | 0.509 | (0.195-1.331) | 0.169 | 1. 064 | (0.112-10.079) | 0.957 |
| Intra-op. complications - Yes | 0.500 | (0.170-1.490) | 0.216 | |||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).